TLSA$0.6718+0.27%
Tiziana Life Sciences Ltd
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: GBExchange: Nasdaq
Mkt Cap:$87.57M
Float & O/S:
Inst Own:
DilutionScan read 43 of Tiziana Life Sciences Ltd's SEC filings and found 3 warrant series, 1 ATM program, 2 shelf registrations and 1 completed offering on file for TLSA. The latest dilution event on file is a warrant issuance on Jan 19, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
TLSA
Clinical biotech with a 2-month cash runway
- Business
- WeakNo revenue, $18.4M net loss, runway 2.3 months
- Stock risk
- High$143M micro-cap, shares +10.9% YoY, 73% dilution overhang
Snapshot
Tiziana is a clinical-stage biotech with no product revenue, running several early-stage trials of its antibody foralumab.
What's Happening Right Now
- : On Oct 16, 2026, Tiziana finished dosing the last patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer's disease, with topline data expected in Q1 2027.
- : On Sep 30, 2026, Tiziana asked the FDA for orphan drug designation for intranasal foralumab in multiple system atrophy, an early regulatory step rather than a clinical decision.
- : On Sep 28, 2026, Tiziana dosed the first three patients in a Phase 2a ALS trial of intranasal foralumab, an early execution milestone with no efficacy data yet.
- : On Sep 21, 2026, the last patient completed final visits in the Phase 2a INFORM-MS trial of intranasal foralumab in secondary progressive MS, setting up a topline data readout.
- : On Jul 31, 2026, Tiziana reported PET imaging showing reduced brain inflammation in a third multiple system atrophy patient treated with intranasal foralumab.
- : Issued warrants over 8.80M shares.
- : Sold 1.21M shares through its at-the-market program, as stated for Jul 1, 2025 to Jan 16, 2026.
- : Sold $10.06M net through its at-the-market program, as stated for Jan 1, 2025 to Dec 31, 2025.
